BNET Industries
- Private
- US
Dow Jones Description
We are a pharmaceutical company focused on developing and commercializing anti-infective drug products that fulfill unmet medical needs. We have developed a proprietary drug delivery technology called PULSYS, which enables pulsatile delivery, or delivery in rapid bursts, of certain drugs. Our PULSYS technology can potentially offer the prolonged release and absorption of a drug. Our near-term corporate strategy is to develop and market drug products that improve dosing regimens and frequency of dosing, which we believe improves patient dosing convenience and compliance for antibiotics that have been used and trusted for decades. Additionally, we are pursuing opportunities to in-license, co-promote or acquire products to more effectively utilize our sales force. We currently have 26 U.S.-issued patents and five foreign patents covering our PULSYS technology, which extend through 2020. Our current PULSYS product, MOXATAG (amoxicillin extended-release) Tablets, 775mg, received U.S. Food and Drug Administration, or FDA, approval for marketing on January 23, 2008, and is the first and only FDA-approved once-daily amoxicillin with no AB-rated generic. It is approved for the treatment of pharyngitis/tonsillitis secondary to Streptococcus pyogenes, commonly known as strep throat, for adults and pediatric patients age 12 and older. ...
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
MiddleBrook Pharmaceuticals Reports Third Quarter 2009 Results
News & Analysis
Filter by
middlebrook pharmaceuticals inc. - All News and Analysis
MiddleBrook Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript
Seeking Alpha
- 2009-11-05
Question-and-Answer SessionOperator Operator Instructions. Your first question comes from the line of [Louis Chen] from Collins Stewart. Louis Chen - Collins Stewart Hi, my first question is with respect to your financing. Can you talk more about the different options that you are looking at and why do you...
MiddleBrook Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript
Seeking Alpha
- 2009-08-06
MiddleBrook Pharmaceuticals, Inc. MBRK Q2 2009 Earnings Call August 6, 2009 9:00 am ET
MiddleBrook Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript
Seeking Alpha
- 2009-08-06
Question-and-Answer SessionOperator Operator Instructions. Your first question comes from the line of Richard Silver from Barclays Capital. Your line is now open. Richard Silver - Barclays Capital Yes. Thank you. A couple of questions. On the operating expense reductions, can you give us a sense of qualitatively what spending...
MiddleBrook Pharmaceuticals, Inc. Q1 2009 Earnings Call Transcript
Seeking Alpha
- 2009-05-07
Question-and-Answer SessionOperator Operator instructions. Your first question comes from Rich Silver. Richard Silver – Barclays Capital Good morning. John Thievon Hi Rich. Richard Silver – Barclays Capital Back to your comment about half of the scrips coming in the fourth quarter can you also give us a sense of...
MiddleBrook Pharmaceuticals, Inc. Q4 2008 Earnings Call Transcript
Seeking Alpha
- 2009-03-05
Question-and-Answer SessionOperator Operator instructions We have no questions in queue. I apologize; our first question does come from the line of Greg Wade of Wedbush Morgan. Your line is open. Greg Wade – Wedbush Morgan Hi, good morning. Greg Wade here, Wedbush Morgan Securities. I was wondering if you...
MiddleBrook Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
Seeking Alpha
- 2008-11-13
Question-and-Answer Session Operator Operator Instructions. We will take our first question from [Menshem Memon] with Interlake Research. Unidentified Analyst I came in late, you said the cash position at the end of the quarter how much was it, was it $75 million? Dave Becker This is Dave. At the...
MiddleBrook Pharmaceuticals Inc. Corporate News: Retained Morgan Stanley as Its Strategic Advisor.
- 2008-02-15
M2 PRESSWIRE-15 February 2008-bellwetherreport.com: MiddleBrook Pharmaceuticals Inc. Corporate News: Retained Morgan Stanley as Its Strategic AdvisorC1994-2008 M2 COMMUNICATIONS LTD RDATE:15022008 Today Bellwether Report has identified MiddleBrook Pharmaceuticals Inc. (NASDAQ:MBRK), a company that our analysts will be tracking over the ensuing...
MiddleBrook Pharmaceuticals, Inc. Review in Progress.
- 2008-01-24
M2 PRESSWIRE-24 January 2008-Market Review: MiddleBrook Pharmaceuticals, Inc. Review in ProgressC1994-2008 M2 COMMUNICATIONS LTD RDATE:24012008 Stocks fell once again Wednesday as investors continue to remain somewhat nervous about the economy. This comes following reports from big names like Apple Inc....
- 1
Industry Transcripts by Seeking Alpha
-
Martek Biosciences Corporation F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 16, 2009about MATK
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Johnson & Johnson |  |
| Merck | |
| Pfizer | |
| Novartis |  |
| Abbott Labs | |
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
Presented by American Express